Description

Simple

Clinical

Overview

Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

Pharmacology

Indication

Investigated for use/treatment in bacterial infection.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Garenoxacin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Garenoxacin.
(S)-Warfarin
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Garenoxacin.
2,4-thiazolidinedione
The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Garenoxacin.
3-isobutyl-1-methyl-7H-xanthine
The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Garenoxacin.
4-hydroxycoumarin
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Garenoxacin.
6-O-benzylguanine
The metabolism of 6-O-benzylguanine can be decreased when combined with Garenoxacin.
7-Deazaguanine
The metabolism of 7-Deazaguanine can be decreased when combined with Garenoxacin.
7,9-Dimethylguanine
The metabolism of 7,9-Dimethylguanine can be decreased when combined with Garenoxacin.
8-azaguanine
The metabolism of 8-azaguanine can be decreased when combined with Garenoxacin.
8-chlorotheophylline
The metabolism of 8-chlorotheophylline can be decreased when combined with Garenoxacin.
9-Deazaguanine
The metabolism of 9-Deazaguanine can be decreased when combined with Garenoxacin.
9-Methylguanine
The metabolism of 9-Methylguanine can be decreased when combined with Garenoxacin.
Abexinostat
The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Abexinostat.
Acarbose
The therapeutic efficacy of Acarbose can be increased when used in combination with Garenoxacin.
Acebutolol
The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Garenoxacin.
Aceclofenac
Aceclofenac may increase the neuroexcitatory activities of Garenoxacin.
Acefylline
The metabolism of Acefylline can be decreased when combined with Garenoxacin.
Acemetacin
Acemetacin may increase the neuroexcitatory activities of Garenoxacin.
Acenocoumarol
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Garenoxacin.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Garenoxacin.